日本化疗学会于2007年开展的全国性细菌呼吸道病原体监测：病原体抗菌药敏概况。
Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility.
作者信息
Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, Watanabe A, Sato J, Hattori R, Terada M, Koashi N, Kozuki T, Maruo A, Morita K, Ogasawara K, Takahashi Y, Watanabe J, Takeuchi K, Fujimura S, Takeda H, Ikeda H, Sato N, Niitsuma K, Saito M, Koshiba S, Kaneko M, Miki M, Nakanowatari S, Honda Y, Chiba J, Takahashi H, Utagawa M, Kondo T, Kawana A, Konosaki H, Aoki Y, Ueda H, Sugiura H, Ichioka M, Goto H, Kurai D, Okazaki M, Yoshida K, Yoshida T, Tanabe Y, Kobayashi S, Okada M, Tsukada H, Imai Y, Honma Y, Nishikawa K, Yamamoto T, Kawai A, Kashiwabara T, Takesue Y, Wada Y, Nakajima K, Miyara T, Toda H, Mitsuno N, Sugimura H, Yoshioka S, Kurokawa M, Munekawa Y, Nakajima H, Kubo S, Ohta Y, Mikasa K, Maeda K, Kasahara K, Koizumi A, Sano R, Yagi S, Takaya M, Kurokawa Y, Kusano N, Mihara E, Kuwabara M, Fujiue Y, Ishimaru T, Matsubara N, Kawasaki Y, Tokuyasu H, Masui K, Negayama K, Ueda N, Ishimaru M, Nakanishi Y, Fujita M, Honda J, Kadota J, Hiramatsu K, Aoki Y, Nagasawa Z, Suga M, Muranaka H, Yanagihara K, Fujita J, Tateyama M, Sunakawa K, Totsuka K
机构信息
The JSC Surveillance Committee, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
出版信息
J Infect Chemother. 2009 Jun;15(3):156-67. doi: 10.1007/s10156-009-0674-z. Epub 2009 Jun 25.
For the purpose of a nationwide surveillance of the antimicrobial susceptibility of bacterial respiratory pathogens in patients in Japan, the Japanese Society of Chemotherapy conducted their second year survey, during the period from January to August, 2007. A total of 1178 strains were collected from clinical specimens obtained from adult patients with well-diagnosed respiratory tract infections. Susceptibility testing was evaluable for 1108 strains (226 Staphylococcus aureus, 257 Streptococcus pneumoniae, 6 Streptococcus pyogenes, 206 Haemophilus influenzae, 120 Moraxella catarrhalis, 122 Klebsiella pneumoniae, and 171 Pseudomonas aeruginosa). A total of 44 antibacterial agents, including 26 beta-lactams (four penicillins, three penicillins in combination with beta-lactamase inhibitors, four oral cephems, eight parenteral cephems, one monobactam, five carbapenems, and one penem), three aminoglycosides, four macrolides (including ketolide), one lincosamide, one tetracycline, two glycopeptides, six fluoroquinolones, and one oxazolidinone were used for the study. Analysis was conducted at the central reference laboratory according to the method recommended by the Clinical and Laboratory Standards Institute (CLSI). The incidence of methicillinresistant Staphylococcus aureus (MRSA) was high, at 59.7%, and the incidences of penicillin-intermediateresistant and -resistant Streptococcus pneumoniae (PISP and PRSP) were 30.4% and 5.1%, respectively. Among Haemophilus influenzae strains, 19.9% of them were found to be beta-lactamase-non-producing ampicillin (ABPC)-intermediately-resistant (BLNAI), 29.1% to be beta-lactamasenon-producing ABPC-resistant (BLNAR), and 6.7% to be beta-lactamase-producing ABPC-resistant (BLPAR) strains. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae was not isolated. Two isolates (1.2%) of Pseudomonas aeruginosa were found to be metallo-beta-lactamase-producing strains, including one (0.6%) suspected multidrug-resistant strain showing resistance to imipenem, amikacin, and ciprofloxacin. These data will be a useful reference for future periodic surveillance studies and for investigations to control resistant infections as well. Continued surveillance is required to prevent the further spread of these antimicrobial resistances.
为在全国范围内监测日本患者中细菌呼吸道病原体的抗菌药物敏感性，日本化疗学会在2007年1月至8月期间开展了第二年的调查。从确诊为呼吸道感染的成年患者的临床标本中总共收集了1178株菌株。对1108株菌株（226株金黄色葡萄球菌、257株肺炎链球菌、6株化脓性链球菌、206株流感嗜血杆菌、120株卡他莫拉菌、122株肺炎克雷伯菌和171株铜绿假单胞菌）进行了药敏试验评估。总共使用了44种抗菌药物进行研究，其中包括26种β-内酰胺类药物（4种青霉素、3种青霉素与β-内酰胺酶抑制剂的组合、4种口服头孢菌素、8种注射用头孢菌素、1种单环β-内酰胺类、5种碳青霉烯类和1种青霉烯类）、3种氨基糖苷类、4种大环内酯类（包括酮内酯）、1种林可酰胺类、1种四环素类、2种糖肽类、6种氟喹诺酮类和1种恶唑烷酮类。由中央参考实验室按照临床和实验室标准协会（CLSI）推荐的方法进行分析。耐甲氧西林金黄色葡萄球菌（MRSA）的发生率很高，为59.7%，青霉素中介耐药和耐药肺炎链球菌（PISP和PRSP）的发生率分别为30.4%和5.1%。在流感嗜血杆菌菌株中，发现19.9%为不产β-内酰胺酶的氨苄西林（ABPC）中介耐药（BLNAI）菌株，29.1%为不产β-内酰胺酶的ABPC耐药（BLNAR）菌株，6.7%为产β-内酰胺酶的ABPC耐药（BLPAR）菌株。未分离出产超广谱β-内酰胺酶的肺炎克雷伯菌。发现2株（1.2%）铜绿假单胞菌为产金属β-内酰胺酶菌株，其中1株（0.6%）疑似多重耐药菌株，对亚胺培南、阿米卡星和环丙沙星耐药。这些数据将为未来的定期监测研究以及控制耐药感染的调查提供有用的参考。需要持续监测以防止这些抗菌药物耐药性的进一步传播。
Zotero 插件